Ncardia Unveils Ncyte Heart in a Box to Transform Heart Research
Netherlands, Monday, 27 January 2025.
Ncardia launches Ncyte Heart in a Box, a novel 3D microtissue model mimicking the human heart, aimed at enhancing cardiovascular research and precision medicine.
Revolutionary Cardiovascular Research Platform
As a significant advancement in healthtech, Leiden-based biotech company Ncardia has launched its groundbreaking Ncyte® Heart in a Box system on January 27, 2025 [1][5]. This innovative platform represents a major leap forward in cardiovascular research by integrating three essential cardiac cell types derived from human-induced pluripotent stem cells (hiPSCs): ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts [1][2].
Advanced Cellular Integration
The system’s uniqueness lies in its ability to create a high-purity 3D cardiac microtissue that accurately replicates the human heart’s complexity and functionality [1][5]. This innovation moves beyond traditional 2D cell cultures, offering researchers a more sophisticated tool for studying heart development and disease progression [1]. The platform’s multi-cellular cardiac model precisely mimics the native human heart microenvironment, providing unprecedented accuracy in cardiovascular research [5].
Applications in Precision Medicine
According to Jeroen de Groot, Divisional CEO of Ncardia, this launch marks a significant milestone in cardiac research innovation [1][5]. The system enables researchers to conduct more predictive and translationally relevant studies, particularly valuable for therapeutic development and safety screening [1]. Ncardia, established in 2011, brings over a decade of expertise in iPSC technology, operating across Europe and North America [4].
Future Impact on Drug Development
The company’s mission aligns with accelerating the discovery and development of new therapeutics across various modalities, including drug, cell, and gene therapy [1][5]. Through the efficient integration of human iPSC technologies, Ncardia aims to bring better therapies to patients faster [4]. The platform’s enhanced predictive power particularly benefits pharmaceutical companies in their drug development process, potentially reducing the time and cost associated with cardiovascular drug testing [1].